JPRN-jRCT2071230090尚未招募1 期
Phase 1, single dose study of M707102 in healthy subjects
ishiura Tomoyuki0 个研究点目标入组 16 人开始时间: 2023年11月19日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 49age old（—）
- 性别
- Male
入选标准
- •Male subjects from 18 to 49 years of age (at the time of informed consent)
排除标准
- •(1) Individuals with a history or complications of any of the following diseases
- •1)Actinic keratosis, porphyria
- •2)Photosensitivity, metabolic diseases such as aminoaciduria, idiopathic or immune diseases such as polymorphic light eruption, genetic diseases such as xeroderma pigmentosum, and diseases for which onset or exacerbation occur due to exposure to sunlight such as systemic lupus erythematosus and pemphigus
- •(2) Individuals with a history of allergy or hypersensitivity (including skin hypersensitivity) to any ingredient or metabolite of the investigational medicinal product
- •(3) Individuals who are judged to be unsuitable as subject by the principal (sub) investigator
研究者
相似试验
招募中
2 期
M201-ASymptomatic Paroxysmal atrial fibrillationJPRN-jRCT2031190069Kumagai Yuji42
已完成
1 期
A Phase 1 study of S-217622COVID-19JPRN-jRCT2031210202agata Tsutae201
未知
1 期
A Phase I Single-Dose Study of RO7046015 in Healthy Japanese MeJPRN-jRCT2080223775CHUGAI PHARMACEUTICAL CO., LTD.24
进行中（未招募）
不适用
Title of the trial for lay people, in easily understood, i.e. non-technical, language: Testing of MZ-004 (investigational product) at different doses in patients who have a completely blocked coronary artery and comparing the results to a placebo or inactive product.The use of MZ-004 to facilitate percutaneous coronary intervention in symptomatic patients with a chronic total occlusion who are indicated for revascularizationEUCTR2014-004649-28-NLMatrizyme Pharma Corporation110
已完成
2 期
A 2-stage study to evaluate single doses of MZ-004 at different dose levels in patients with chronic total occlusions. STAGE 1: Open label Training Stage. STAGE 2: Double-blind, randomized, Placebo-Controlled Stage. The TOSCA-5 Study (Total Occlusion Study in Coronary Arteries-5)NL-OMON41937Matrizyme Pharma Corp.25